Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) rose 4.9% during mid-day trading on Wednesday . The company traded as high as $11.56 and last traded at $11.56, with a volume of 124,460 shares traded. The stock had previously closed at $11.02.

SCMP has been the topic of a number of recent analyst reports. Roth Capital reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Tuesday, July 12th. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday, July 11th. Maxim Group reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday, July 11th. WallachBeth Capital raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Thursday, May 5th. Finally, Guggenheim reissued a “buy” rating and issued a $29.00 price target on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Sucampo Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.00.

The firm has a market cap of $494.93 million and a price-to-earnings ratio of 22.99. The company’s 50-day moving average price is $11.23 and its 200 day moving average price is $11.84.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.02. During the same period last year, the company earned $0.14 EPS. The business earned $47.20 million during the quarter, compared to the consensus estimate of $44.11 million. The business’s revenue was up 60.0% compared to the same quarter last year. On average, equities analysts predict that Sucampo Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.

A number of institutional investors have made changes to their positions in SCMP. Shell Asset Management Co. acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at approximately $1,324,000. GSA Capital Partners LLP increased its position in shares of Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock valued at $3,802,000 after buying an additional 17,172 shares during the period. Globeflex Capital L P increased its position in shares of Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 28,431 shares during the period. Finally, Systematic Financial Management LP increased its position in shares of Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock valued at $1,759,000 after buying an additional 15,590 shares during the period.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.